[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:follicular-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":311,"states":334},"Follicular Lymphoma",137,119,[8,16,23,30,37,43,49,55,61,67,73,79,85,91,97,103,109,115,122,128,134,140,146,152,158,164,170,176,182,188,194,200,206,212,217,223,229,235,241,247,253,259,264,270,276,282,288,294,300,305],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06526793","Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed\u002FRefractory (R\u002FR) B-cell NHL",[12],"Phase 2","RECRUITING","2026-08-26T02:15:36.077529Z","2026-07-05T05:32:16.757959Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06447376","Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab",[20],"Phase 1","2026-08-26T02:17:18.747857Z","2026-07-05T05:32:16.755616Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06911502","A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed\u002FRefractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)",[27],"Phase 3","2026-08-26T02:16:09.452956Z","2026-07-05T05:32:16.702356Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":35,"content_modified":36},"NCT07634471","A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)",[34],"Phase 2\u002FPhase 3","2026-08-26T02:19:10.436356Z","2026-07-05T03:45:20.255789Z",{"nct_id":38,"title":39,"phases":40,"status":13,"updated_at":41,"content_modified":42},"NCT07343934","huCART19-IL18-eDHFR Cells in Relapsed\u002FRefractory Follicular Lymphoma",[20],"2026-08-26T02:15:46.655893Z","2026-05-29T15:36:40.186042Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT05389293","A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma",[12],"2026-08-26T02:19:14.560989Z","2026-05-05T02:43:29.733361Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT06350318","Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas",[12],"2026-08-26T02:17:56.243868Z","2026-05-05T02:43:29.381547Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT06337318","Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma",[27],"2026-08-26T02:16:51.982021Z","2026-05-05T02:43:29.370223Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06149286","A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma",[27],"2026-08-26T02:19:19.162260Z","2026-05-05T02:43:29.214083Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT07029217","A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas",[27],"2026-08-26T02:16:31.714843Z","2026-05-05T02:43:28.883520Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT04587687","Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma",[12],"2026-08-26T02:16:54.044282Z","2026-05-05T02:43:28.811399Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06091254","A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma",[27],"2026-08-26T02:18:58.141497Z","2026-05-05T02:43:28.416255Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT06792825","HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL",[12],"2026-08-26T02:18:08.005333Z","2026-05-05T02:43:28.357811Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT06191744","Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma",[27],"2026-08-03T03:17:24.376136Z","2026-05-05T02:43:28.302501Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT05783609","Epcoritamab and Rituximab for First-line Follicular Lymphoma",[12],"2026-08-26T02:17:22.949982Z","2026-05-05T02:43:28.212024Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT06563596","Epco, Zanu, Ritux for R\u002FR FL or MZL",[12],"2026-08-26T02:18:38.865010Z","2026-05-05T02:43:28.189974Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT06453044","Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma",[12],"2026-08-26T02:18:27.904411Z","2026-05-05T02:43:28.118057Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":120,"content_modified":121},"NCT04669171","A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma",[119],"Phase 1\u002FPhase 2","2026-08-26T02:16:40.941792Z","2026-05-05T02:43:28.101658Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT06854159","Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy",[12],"2026-08-26T02:15:33.331531Z","2026-05-05T02:43:27.997454Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT06510361","Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy",[12],"2026-08-26T02:15:31.806698Z","2026-05-05T02:43:27.657581Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT07128641","Odronextamab in Low Tumor Volume Advanced FL",[12],"2026-08-26T02:18:24.494016Z","2026-05-05T02:43:27.423636Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT06043323","A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed\u002FRefractory Follicular Lymphoma",[12],"2026-08-26T02:18:15.214990Z","2026-05-05T02:43:26.973410Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT06549595","A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients",[27],"2026-08-26T02:18:26.932189Z","2026-05-05T02:43:26.961950Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT04998669","Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma",[12],"2026-08-26T02:15:59.318403Z","2026-04-29T02:57:57.151812Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":162,"content_modified":163},"NCT06442475","Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma",[12],"2026-08-26T02:17:01.714035Z","2026-04-29T02:57:57.111905Z",{"nct_id":165,"title":166,"phases":167,"status":13,"updated_at":168,"content_modified":169},"NCT05365659","IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas",[20],"2026-08-26T02:18:09.641312Z","2026-07-30T01:46:14.462340Z",{"nct_id":171,"title":172,"phases":173,"status":13,"updated_at":174,"content_modified":175},"NCT06948786","Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed\u002FRefractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial",[12],"2026-08-26T02:17:32.059863Z","2026-07-05T05:32:16.721320Z",{"nct_id":177,"title":178,"phases":179,"status":13,"updated_at":180,"content_modified":181},"NCT07226843","A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers",[20],"2026-08-26T02:15:58.452248Z","2026-07-05T05:32:16.666342Z",{"nct_id":183,"title":184,"phases":185,"status":13,"updated_at":186,"content_modified":187},"NCT03571568","A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL",[119],"2026-08-26T02:18:38.077159Z","2026-05-05T02:43:29.721924Z",{"nct_id":189,"title":190,"phases":191,"status":13,"updated_at":192,"content_modified":193},"NCT06550141","Emapalumab Prevention of CAR-T Cell Associated Toxicities",[12],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:29.284441Z",{"nct_id":195,"title":196,"phases":197,"status":13,"updated_at":198,"content_modified":199},"NCT06828991","A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP",[12],"2026-08-26T02:17:35.666428Z","2026-05-05T02:43:29.283059Z",{"nct_id":201,"title":202,"phases":203,"status":13,"updated_at":204,"content_modified":205},"NCT05512390","A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R\u002FR) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)",[20],"2026-08-26T02:17:30.145302Z","2026-05-05T02:43:29.159145Z",{"nct_id":207,"title":208,"phases":209,"status":13,"updated_at":210,"content_modified":211},"NCT05370430","BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL",[20],"2026-08-26T02:15:47.754948Z","2026-05-05T02:43:28.804231Z",{"nct_id":213,"title":214,"phases":215,"status":13,"updated_at":47,"content_modified":216},"NCT05890352","Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment",[12],"2026-05-05T02:43:28.725480Z",{"nct_id":218,"title":219,"phases":220,"status":13,"updated_at":221,"content_modified":222},"NCT03758989","A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma",[12],"2026-08-26T02:16:50.548894Z","2026-05-05T02:43:28.176656Z",{"nct_id":224,"title":225,"phases":226,"status":13,"updated_at":227,"content_modified":228},"NCT07283679","Phase I\u002FII Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",[119],"2026-08-26T02:18:03.638950Z","2026-05-05T02:43:27.977643Z",{"nct_id":230,"title":231,"phases":232,"status":13,"updated_at":233,"content_modified":234},"NCT06905509","Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma",[12],"2026-08-26T02:15:13.282904Z","2026-05-05T02:43:27.809747Z",{"nct_id":236,"title":237,"phases":238,"status":13,"updated_at":239,"content_modified":240},"NCT03460977","A Study of Mevrometostat for Treatment of Relapsed\u002FRefractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma",[20],"2026-08-26T02:15:44.309045Z","2026-05-05T02:43:27.599003Z",{"nct_id":242,"title":243,"phases":244,"status":13,"updated_at":245,"content_modified":246},"NCT05615636","A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL",[12],"2026-08-26T02:17:23.750999Z","2026-05-05T02:43:27.476441Z",{"nct_id":248,"title":249,"phases":250,"status":13,"updated_at":251,"content_modified":252},"NCT05633615","Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma",[12],"2026-08-26T02:18:23.582895Z","2026-05-05T02:43:27.059186Z",{"nct_id":254,"title":255,"phases":256,"status":13,"updated_at":257,"content_modified":258},"NCT07042438","Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells",[12],"2026-08-26T02:15:11.740957Z","2026-05-05T02:35:31.730111Z",{"nct_id":260,"title":261,"phases":262,"status":13,"updated_at":186,"content_modified":263},"NCT06784726","Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T",[12],"2026-05-05T02:35:31.722685Z",{"nct_id":265,"title":266,"phases":267,"status":13,"updated_at":268,"content_modified":269},"NCT04792502","Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma",[12],"2026-08-26T02:15:03.757872Z","2026-04-29T02:57:57.106355Z",{"nct_id":271,"title":272,"phases":273,"status":13,"updated_at":274,"content_modified":275},"NCT04792489","DALY II USA\u002F MB-CART2019.1 for DLBCL",[12],"2026-08-26T02:16:01.910993Z","2026-07-19T19:36:05.118465Z",{"nct_id":277,"title":278,"phases":279,"status":13,"updated_at":280,"content_modified":281},"NCT05006716","A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies",[119],"2026-08-26T02:17:24.721169Z","2026-07-05T05:32:16.799692Z",{"nct_id":283,"title":284,"phases":285,"status":13,"updated_at":286,"content_modified":287},"NCT06615050","A Study of Tacrolimus\u002FMethotrexate\u002FRuxolitinib Versus Post-Transplant Cyclophosphamide\u002FTacrolimus\u002FMycophenolate Mofetil in Non-Myeloablative\u002FReduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)",[27],"2026-08-26T02:16:04.914942Z","2026-07-05T05:32:16.764159Z",{"nct_id":289,"title":290,"phases":291,"status":13,"updated_at":292,"content_modified":293},"NCT07123454","A Phase I\u002FII Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed\u002FRefractory B-cell Non-Hodgkin Lymphoma",[119],"2026-08-26T02:19:29.119921Z","2026-07-05T05:32:16.737268Z",{"nct_id":295,"title":296,"phases":297,"status":13,"updated_at":298,"content_modified":299},"NCT07101328","A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )",[20],"2026-08-26T02:15:54.846520Z","2026-07-05T05:32:16.733199Z",{"nct_id":301,"title":302,"phases":303,"status":13,"updated_at":35,"content_modified":304},"NCT06801002","Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies",[20],"2026-05-05T02:43:29.672207Z",{"nct_id":306,"title":307,"phases":308,"status":13,"updated_at":309,"content_modified":310},"NCT06712810","Q702 for the Treatment of Patients With Hematologic Malignancies",[20],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:29.581486Z",[312,316,320,324,327,331],{"biomarker":313,"count":314,"slug":315},"MS4A1 Gene",16,"ms4a1-gene",{"biomarker":317,"count":318,"slug":319},"CD19 Gene",15,"cd19-gene",{"biomarker":321,"count":322,"slug":323},"BCL2 Gene",4,"bcl2-gene",{"biomarker":325,"count":322,"slug":326},"MYC Gene","myc-gene",{"biomarker":328,"count":329,"slug":330},"BCL6 Gene",3,"bcl6-gene",{"biomarker":332,"count":329,"slug":333},"HIV Infection","hiv-infection",[335,339,343,347,351,355,359,363,367,371,375,378,382,386,390,394,397,400,404,407,410,413,416,419],{"state":336,"count":337,"slug":338},"California",50,"california",{"state":340,"count":341,"slug":342},"Texas",48,"texas",{"state":344,"count":345,"slug":346},"New York",45,"new-york",{"state":348,"count":349,"slug":350},"Ohio",38,"ohio",{"state":352,"count":353,"slug":354},"Florida",35,"florida",{"state":356,"count":357,"slug":358},"North Carolina",30,"north-carolina",{"state":360,"count":361,"slug":362},"Washington",28,"washington",{"state":364,"count":365,"slug":366},"Tennessee",27,"tennessee",{"state":368,"count":369,"slug":370},"Wisconsin",26,"wisconsin",{"state":372,"count":373,"slug":374},"Minnesota",25,"minnesota",{"state":376,"count":373,"slug":377},"Pennsylvania","pennsylvania",{"state":379,"count":380,"slug":381},"Massachusetts",23,"massachusetts",{"state":383,"count":384,"slug":385},"Georgia",21,"georgia",{"state":387,"count":388,"slug":389},"New Jersey",20,"new-jersey",{"state":391,"count":392,"slug":393},"Maryland",19,"maryland",{"state":395,"count":392,"slug":396},"Michigan","michigan",{"state":398,"count":392,"slug":399},"Virginia","virginia",{"state":401,"count":402,"slug":403},"Arizona",17,"arizona",{"state":405,"count":402,"slug":406},"Colorado","colorado",{"state":408,"count":402,"slug":409},"Illinois","illinois",{"state":411,"count":402,"slug":412},"Oregon","oregon",{"state":414,"count":314,"slug":415},"Iowa","iowa",{"state":417,"count":314,"slug":418},"Missouri","missouri",{"state":420,"count":314,"slug":421},"Utah","utah"]